This course has expired. View available courses.
Medication Management
Optimizing the Intraoperative Management of Neuromuscular Blockade in High-Risk Patients
This program supports Canadian pharmacists in optimizing their knowledge of the intraoperative management of neuromuscular blockade and the medications used to reverse neuromuscular blockade (neuromuscular reversal agents). This program focuses on high-risk patient populations and the efficacy and safety considerations when managing neuromuscular blockade in these patients. The efficacy and limitations of neuromuscular reversal agents […]
DURATION
1.5 hours
PROFESSION
Pharmacy
# OF CREDITS
1.5
ACCREDITATION
CCCEP
EXPIRY DATE
2021-12-16
This program supports Canadian pharmacists in optimizing their knowledge of the intraoperative management of neuromuscular blockade and the medications used to reverse neuromuscular blockade (neuromuscular reversal agents). This program focuses on high-risk patient populations and the efficacy and safety considerations when managing neuromuscular blockade in these patients.
The efficacy and limitations of neuromuscular reversal agents will be illustrated through case-based learning, to increase comfort and confidence in knowledgably using these medications.
This program has received an educational grant or in-kind support from Merck.
Faculty
Claude Laflamme, MD, FRCPC
Eric Romeril, BSc.Pharm
Amine Bouziane, B. PHARM, M.Sc
Learning objectives
On completion of this program, participants will be able to:
- Describe the mode of action of neuromuscular blocking agents and neuromuscular reversal agents
- Define high-risk patient populations in the operating room
- Highlight the challenges and opportunities in the management of neuromuscular blockade in high-risk patient populations
Accreditation
This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 1.50 CEU.CCCEP File Number: 1066-2020-3125-I-P